Top

Published in:

Open Access 01-12-2013 | Research

Activation of cyclin-dependent kinase 5 mediates orofacial mechanical hyperalgesia

Authors: Michaela Prochazkova, Anita Terse, Niranjana D Amin, Bradford Hall, Elias Utreras, Harish C Pant, Ashok B Kulkarni

Published in: Molecular Pain | Issue 1/2013

Abstract

Background

Cyclin-dependent kinase 5 (Cdk5) is a unique member of the serine/threonine kinase family. This kinase plays an important role in neuronal development, and deregulation of its activity leads to neurodegenerative disorders. Cdk5 also serves an important function in the regulation of nociceptive signaling. Our previous studies revealed that the expression of Cdk5 and its activator, p35, is upregulated in nociceptive neurons during peripheral inflammation. The aim of the present study was to characterize the involvement of Cdk5 in orofacial pain. Since mechanical hyperalgesia is the distinctive sign of many orofacial pain conditions, we adapted an existing orofacial stimulation test to assess the behavioral responses to mechanical stimulation in the trigeminal region of the transgenic mice with either reduced or increased Cdk5 activity.

Results

Mice overexpressing or lacking p35, an activator of Cdk5, showed altered phenotype in response to noxious mechanical stimulation in the trigeminal area. Mice with increased Cdk5 activity displayed aversive behavior to mechanical stimulation as indicated by a significant decrease in reward licking events and licking time. The number of reward licking/facial contact events was significantly decreased in these mice as the mechanical intensity increased. By contrast, mice deficient in Cdk5 activity displayed mechanical hypoalgesia.

Conclusions

Collectively, our findings demonstrate for the first time the important role of Cdk5 in orofacial mechanical nociception. Modulation of Cdk5 activity in primary sensory neurons makes it an attractive potential target for the development of novel analgesics that could be used to treat multiple orofacial pain conditions.

Available only for authorised users

Madland G, Newton-John T, Feinmann C: Chronic idiopathic orofacial pain: I: what is the evidence base? Br Dent J 2001, 191: 22–24.PubMed

Kohlmann T: Epidemiology of orofacial pain. Schmerz 2002, 16: 339–345. 10.1007/s004820200000CrossRefPubMed

Romero-Reyes M, Akerman S, Nguyen E, Vijjeswarapu A, Hom B, Dong HW, Charles AC: Spontaneous behavioral responses in the orofacial region: a model of trigeminal pain in mouse. Headache 2013, 53: 137–151. 10.1111/j.1526-4610.2012.02226.xPubMedCentralCrossRefPubMed

Yasuda M, Shinoda M, Kiyomoto M, Honda K, Suzuki A, Tamagawa T, Kaji K, Kimoto S, Iwata K: P2X3 receptor mediates ectopic mechanical allodynia with inflamed lower lip in mice. Neurosci Lett 2012, 528: 67–72. 10.1016/j.neulet.2012.08.067CrossRefPubMed

Poh KW, Lutfun N, Manikandan J, Ong WY, Yeo JF: Global gene expression analysis in the mouse brainstem after hyperalgesia induced by facial carrageenan injection–evidence for a form of neurovascular coupling? Pain 2009, 142: 133–141. 10.1016/j.pain.2008.12.029CrossRefPubMed

Poh KW, Yeo JF, Stohler CS, Ong WY: Comprehensive gene expression profiling in the prefrontal cortex links immune activation and neutrophil infiltration to antinociception. J Neurosci 2012, 32: 35–45. 10.1523/JNEUROSCI.2389-11.2012CrossRefPubMed

Bornhof M, Ihmsen H, Schwilden H, Yeomans DC, Tzabazis A: The orofacial formalin test in mice revisited–effects of formalin concentration, age, morphine and analysis method. J Pain 2011, 12: 633–639. 10.1016/j.jpain.2010.11.009CrossRefPubMed

Luccarini P, Childeric A, Gaydier AM, Voisin D, Dallel R: The orofacial formalin test in the mouse: a behavioral model for studying physiology and modulation of trigeminal nociception. J Pain 2006, 7: 908–914. 10.1016/j.jpain.2006.04.010CrossRefPubMed

Miranda HF, Noriega V, Sierralta F, Prieto JC: Interaction between dexibuprofen and dexketoprofen in the orofacial formalin test in mice. Pharmacol Biochem Behav 2011, 97: 423–427. 10.1016/j.pbb.2010.09.017CrossRefPubMed

10.

Miranda HF, Noriega V, Zepeda RJ, Sierralta F, Prieto JC: Systemic synergism between codeine and morphine in three pain models in mice. Pharmacol Rep 2013, 65: 80–88.CrossRefPubMed

11.

Cha M, Kohan KJ, Zuo X, Ling JX, Gu JG: Assessment of chronic trigeminal neuropathic pain by the orofacial operant test in rats. Behav Brain Res 2012, 234: 82–90. 10.1016/j.bbr.2012.06.020PubMedCentralCrossRefPubMed

12.

Krzyzanowska A, Pittolo S, Cabrerizo M, Sanchez-Lopez J, Krishnasamy S, Venero C, Avendano C: Assessing nociceptive sensitivity in mouse models of inflammatory and neuropathic trigeminal pain. J Neurosci Methods 2011, 201: 46–54. 10.1016/j.jneumeth.2011.07.006CrossRefPubMed

13.

Rossi HL, Jenkins AC, Kaufman J, Bhattacharyya I, Caudle RM, Neubert JK: Characterization of bilateral trigeminal constriction injury using an operant facial pain assay. Neuroscience 2012, 224: 294–306.CrossRefPubMed

14.

Teodoro FC, Tronco Junior MF, Zampronio AR, Martini AC, Rae GA, Chichorro JG: Peripheral substance P and neurokinin-1 receptors have a role in inflammatory and neuropathic orofacial pain models. Neuropeptides 2013, 47: 199–206. 10.1016/j.npep.2012.10.005CrossRefPubMed

15.

Neubert JK, King C, Malphurs W, Wong F, Weaver JP, Jenkins AC, Rossi HL, Caudle RM: Characterization of mouse orofacial pain and the effects of lesioning TRPV1-expressing neurons on operant behavior. Mol Pain 2008, 4: 43. 10.1186/1744-8069-4-43PubMedCentralCrossRefPubMed

16.

Neubert JK, Widmer CG, Malphurs W, Rossi HL, Vierck CJ Jr, Caudle RM: Use of a novel thermal operant behavioral assay for characterization of orofacial pain sensitivity. Pain 2005, 116: 386–395. 10.1016/j.pain.2005.05.011CrossRefPubMed

17.

Nolan TA, Hester J, Bokrand-Donatelli Y, Caudle RM, Neubert K: Adaptation of novel operant orofacial testing system to characterize both mechanical and thermal pain. Behav Brain Res 2011, 217: 477–480. 10.1016/j.bbr.2010.10.022PubMedCentralCrossRefPubMed

18.

Rossi HL, Vierck CJ Jr, Caudle RM, Neubert JK: Characterization of cold sensitivity and thermal preference using an operant orofacial assay. Mol Pain 2006, 2: 37. 10.1186/1744-8069-2-37PubMedCentralCrossRefPubMed

19.

Dhariwala FA, Rajadhyaksha MS: An unusual member of the Cdk family: Cdk5. Cell Mol Neurobiol 2008, 28: 351–369. 10.1007/s10571-007-9242-1CrossRefPubMed

20.

Dhavan R, Tsai LH: A decade of CDK5. Nat Rev Mol Cell Biol 2001, 2: 749–759. 10.1038/35096019CrossRefPubMed

21.

Lalioti V, Pulido D, Sandoval IV: Cdk5, the multifunctional surveyor. Cell Cycle 2010, 9: 284–311. 10.4161/cc.9.2.10466CrossRefPubMed

22.

Liebl J, Furst R, Vollmar AM, Zahler S: Twice switched at birth: cell cycle-independent roles of the “neuron-specific” cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells. Cell Signal 2011, 23: 1698–1707. 10.1016/j.cellsig.2011.06.020CrossRefPubMed

23.

Su SC, Tsai LH: Cyclin-dependent kinases in brain development and disease. Annu Rev Cell Dev Biol 2011, 27: 465–491. 10.1146/annurev-cellbio-092910-154023CrossRefPubMed

24.

Arif A: Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase Cdk5. Biochem Pharmacol 2012, 84: 985–993. 10.1016/j.bcp.2012.06.027CrossRefPubMed

25.

Contreras-Vallejos E, Utreras E, Gonzalez-Billault C: Going out of the brain: non-nervous system physiological and pathological functions of Cdk5. Cell Signal 2012, 24: 44–52. 10.1016/j.cellsig.2011.08.022CrossRefPubMed

26.

Rosales JL, Lee KY: Extraneuronal roles of cyclin-dependent kinase 5. Bioessays 2006, 28: 1023–1034. 10.1002/bies.20473CrossRefPubMed

27.

Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna , Pant HC, Brady RO, Martin LJ, Kulkarni AB: Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA 1996, 93: 11173–11178. 10.1073/pnas.93.20.11173PubMedCentralCrossRefPubMed

28.

Takahashi S, Ohshima T, Cho A, Sreenath T, Iadarola MJ, Pant HC, Kim Y, Nairn AC, Brady RO, Greengard P, Kulkarni AB: Increased activity of cyclin-dependent kinase 5 leads to attenuation of cocaine-mediated dopamine signaling. Proc Natl Acad Sci USA 2005, 102: 1737–1742. 10.1073/pnas.0409456102PubMedCentralCrossRefPubMed

29.

Chae T, Kwon YT, Bronson R, Dikkes P, Li E, Tsai LH: Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 1997, 18: 29–42. 10.1016/S0896-6273(01)80044-1CrossRefPubMed

30.

Pareek TK, Keller J, Kesavapany S, Agarwal N, Kuner R, Pant HC, Iadarola MJ, Brady RO, Kulkarni AB: Cyclin-dependent kinase 5 modulates nociceptive signaling through direct phosphorylation of transient receptor potential vanilloid 1. Proc Natl Acad Sci USA 2007, 104: 660–665. 10.1073/pnas.0609916104PubMedCentralCrossRefPubMed

31.

Yang YR, He Y, Zhang Y, Li Y, Li Y, Han Y, Zhu H, Wang Y: Activation of cyclin-dependent kinase 5 (Cdk5) in primary sensory and dorsal horn neurons by peripheral inflammation contributes to heat hyperalgesia. Pain 2007, 127: 109–120. 10.1016/j.pain.2006.08.008CrossRefPubMed

32.

Pareek TK, Keller J, Kesavapany S, Pant HC, Iadarola MJ, Brady RO, Kulkarni AB: Cyclin-dependent kinase 5 activity regulates pain signaling. Proc Natl Acad Sci USA 2006, 103: 791–796. 10.1073/pnas.0510405103PubMedCentralCrossRefPubMed

33.

Maccioni RB, Otth C, Concha II, Munoz JP: The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer’s pathology. Eur J Biochem 2001, 268: 1518–1527. 10.1046/j.1432-1327.2001.02024.xCrossRefPubMed

34.

Langford DJ, Bailey AL, Chanda ML, Clarke SE, Drummond TE, Echols S, Glick S, Ingrao J, Klassen-Ross T, Lacroix-Fralish ML, et al.: Coding of facial expressions of pain in the laboratory mouse. Nat Methods 2010, 7: 447–449. 10.1038/nmeth.1455CrossRefPubMed

35.

Dolan JC, Lam DK, Achdjian SH, Schmidt BL: The dolognawmeter: a novel instrument and assay to quantify nociception in rodent models of orofacial pain. J Neurosci Methods 2010, 187: 207–215. 10.1016/j.jneumeth.2010.01.012PubMedCentralCrossRefPubMed

36.

Ambalavanar R, Moritani M, Dessem D: Trigeminal P2X3 receptor expression differs from dorsal root ganglion and is modulated by deep tissue inflammation. Pain 2005, 117: 280–291. 10.1016/j.pain.2005.06.029CrossRefPubMed

37.

Harriott AM, Gold MS: Serotonin type 1D receptors (5HTR) are differentially distributed in nerve fibres innervating craniofacial tissues. Cephalalgia 2008, 28: 933–944. 10.1111/j.1468-2982.2008.01635.xPubMedCentralCrossRefPubMed

38.

Harriott AM, Gold MS: Electrophysiological properties of dural afferents in the absence and presence of inflammatory mediators. J Neurophysiol 2009, 101: 3126–3134. 10.1152/jn.91339.2008PubMedCentralCrossRefPubMed

39.

Wang CH, Chou WY, Hung KS, Jawan B, Lu CN, Liu JK, Hung YP, Lee TH: Intrathecal administration of roscovitine inhibits Cdk5 activity and attenuates formalin-induced nociceptive response in rats. Acta Pharmacol Sin 2005, 26: 46–50. 10.1111/j.1745-7254.2005.00007.xCrossRefPubMed

40.

Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389: 816–824. 10.1038/39807CrossRefPubMed

41.

Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D: The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998, 21: 531–543. 10.1016/S0896-6273(00)80564-4CrossRefPubMed

42.

Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, Julius D: Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000, 288: 306–313. 10.1126/science.288.5464.306CrossRefPubMed

43.

Xing BM, Yang YR, Du JX, Chen HJ, Qi C, Huang ZH, Zhang Y, Wang Y: Cyclin-dependent kinase 5 controls TRPV1 membrane trafficking and the heat sensitivity of nociceptors through KIF13B. J Neurosci 2012, 32: 14709–14721. 10.1523/JNEUROSCI.1634-12.2012CrossRefPubMed

44.

Cui M, Honore P, Zhong C, Gauvin D, Mikusa J, Hernandez G, Chandran P, Gomtsyan A, Brown B, Bayburt EK, et al.: TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J Neurosci 2006, 26: 9385–9393. 10.1523/JNEUROSCI.1246-06.2006CrossRefPubMed

45.

Watabiki T, Kiso T, Tsukamoto M, Aoki T, Matsuoka N: Intrathecal administration of AS1928370, a transient receptor potential vanilloid 1 antagonist, attenuates mechanical allodynia in a mouse model of neuropathic pain. Biol Pharm Bull 2011, 34: 1105–1108. 10.1248/bpb.34.1105CrossRefPubMed

46.

Yu L, Yang F, Luo H, Liu FY, Han JS, Xing GG, Wan Y: The role of TRPV1 in different subtypes of dorsal root ganglion neurons in rat chronic inflammatory nociception induced by complete Freund’s adjuvant. Mol Pain 2008, 4: 61. 10.1186/1744-8069-4-61PubMedCentralCrossRefPubMed

47.

Ro JY, Lee JS, Zhang Y: Activation of TRPV1 and TRPA1 leads to muscle nociception and mechanical hyperalgesia. Pain 2009, 144: 270–277. 10.1016/j.pain.2009.04.021PubMedCentralCrossRefPubMed

48.

Saloman JL, Chung MK, Ro JY: P2X (3) and TRPV1 functionally interact and mediate sensitization of trigeminal sensory neurons. Neuroscience 2012, 232: 226–238.CrossRefPubMed

49.

Lee J, Saloman JL, Weiland G, Auh QS, Chung MK, Ro JY: Functional interactions between NMDA receptors and TRPV1 in trigeminal sensory neurons mediate mechanical hyperalgesia in the rat masseter muscle. Pain 2012, 153: 1514–1524. 10.1016/j.pain.2012.04.015PubMedCentralCrossRefPubMed

50.

Kim SH, Ryan TA: CDK5 serves as a major control point in neurotransmitter release. Neuron 2010, 67: 797–809. 10.1016/j.neuron.2010.08.003PubMedCentralCrossRefPubMed

51.

Kim SH, Ryan TA: Balance of calcineurin aalpha and CDK5 activities sets release probability at nerve terminals. J Neurosci 2013, 33: 8937–8950. 10.1523/JNEUROSCI.4288-12.2013CrossRefPubMed

52.

Zhang HH, Zhang XQ, Wang WY, Xue QS, Lu H, Huang JL, Gui T, Yu BW: Increased synaptophysin is involved in inflammation-induced heat hyperalgesia mediated by cyclin-dependent kinase 5 in rats. PLoS One 2012, 7: e46666. 10.1371/journal.pone.0046666PubMedCentralCrossRefPubMed

53.

Chen HJ, Xie WY, Hu F, Zhang Y, Wang J, Wang Y: Disruption of delta-opioid receptor phosphorylation at threonine 161 attenuates morphine tolerance in rats with CFA-induced inflammatory hypersensitivity. Neurosci Bull 2012, 28: 182–192. 10.1007/s12264-012-1216-8CrossRefPubMed

54.

Xie WY, He Y, Yang YR, Li YF, Kang K, Xing BM, Wang Y: Disruption of Cdk5-associated phosphorylation of residue threonine-161 of the delta-opioid receptor: impaired receptor function and attenuated morphine antinociceptive tolerance. J Neurosci 2009, 29: 3551–3564. 10.1523/JNEUROSCI.0415-09.2009CrossRefPubMed

55.

Zhang R, Liu Y, Zhang J, Zheng Y, Gu X, Ma Z: Intrathecal administration of roscovitine attenuates cancer pain and inhibits the expression of NMDA receptor 2B subunit mRNA. Pharmacol Biochem Behav 2012, 102: 139–145. 10.1016/j.pbb.2012.03.025CrossRefPubMed

56.

Zhang S, Edelmann L, Liu J, Crandall JE, Morabito MA: Cdk5 regulates the phosphorylation of tyrosine 1472 NR2B and the surface expression of NMDA receptors. J Neurosci 2008, 28: 415–424. 10.1523/JNEUROSCI.1900-07.2008CrossRefPubMed

57.

Nair A, Simonetti M, Fabbretti E, Nistri A: The Cdk5 kinase downregulates ATP-gated ionotropic P2X3 receptor function via serine phosphorylation. Cell Mol Neurobiol 2010, 30: 505–509. 10.1007/s10571-009-9483-2CrossRefPubMed

58.

Tomizawa K, Ohta J, Matsushita M, Moriwaki A, Li ST, Takei K, Matsui H: Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity. J Neurosci 2002, 22: 2590–2597.PubMed

59.

Brierley SM, Castro J, Harrington AM, Hughes PA, Page AJ, Rychkov GY, Blackshaw LA: TRPA1 contributes to specific mechanically activated currents and sensory neuron mechanical hypersensitivity. J Physiol 2011, 589: 3575–3593. 10.1113/jphysiol.2011.206789PubMedCentralCrossRefPubMed

60.

Brierley SM, Hughes PA, Page AJ, Kwan KY, Martin CM, O’Donnell TA, Cooper NJ, Harrington AM, Adam B, Liebregts T, et al.: The ion channel TRPA1 is required for normal mechanosensation and is modulated by algesic stimuli. Gastroenterology 2009, 137: 2084–2095. e2083 10.1053/j.gastro.2009.07.048PubMedCentralCrossRefPubMed

61.

Kwan KY, Glazer JM, Corey DP, Rice FL, Stucky CL: TRPA1 modulates mechanotransduction in cutaneous sensory neurons. J Neurosci 2009, 29: 4808–4819. 10.1523/JNEUROSCI.5380-08.2009PubMedCentralCrossRefPubMed

62.

Alloui A, Zimmermann K, Mamet J, Duprat F, Noel J, Chemin J, Guy N, Blondeau N, Voilley N, Rubat-Coudert C, et al.: TREK-1, a K + channel involved in polymodal pain perception. EMBO J 2006, 25: 2368–2376. 10.1038/sj.emboj.7601116PubMedCentralCrossRefPubMed

63.

Dedman A, Sharif-Naeini R, Folgering JH, Duprat F, Patel A, Honore E: The mechano-gated K (2P) channel TREK-1. Eur Biophys J 2009, 38: 293–303. 10.1007/s00249-008-0318-8CrossRefPubMed

64.

Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16: 109–110. 10.1016/0304-3959(83)90201-4CrossRefPubMed

65.

Nolan TA, Caudle RM, Neubert JK: Effect of caloric and non-caloric sweet reward solutions on thermal facial operant conditioning. Behav Brain Res 2011, 216: 723–725. 10.1016/j.bbr.2010.08.023PubMedCentralCrossRefPubMed

66.

Veeranna A, Shetty KT, Amin N, Grant P, Albers RW, Pant HC: Inhibition of neuronal cyclin-dependent kinase-5 by staurosporine and purine analogs is independent of activation by Munc-18. Neurochem Res 1996, 21: 629–636. 10.1007/BF02527763CrossRefPubMed

Title: Activation of cyclin-dependent kinase 5 mediates orofacial mechanical hyperalgesia
Authors: Michaela Prochazkova
Anita Terse
Niranjana D Amin
Bradford Hall
Elias Utreras
Harish C Pant
Ashok B Kulkarni
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Molecular Pain / Issue 1/2013
Electronic ISSN: 1744-8069
DOI: https://doi.org/10.1186/1744-8069-9-66

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Activation of cyclin-dependent kinase 5 mediates orofacial mechanical hyperalgesia

Abstract

Background

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Reviewer acknowledgement

Involvement of TRPA1 activation in acute pain induced by cadmium in mice

No evidence for the development of acute analgesic tolerance during and hyperalgesia after prolonged remifentanil administration in mice

Genome-wide association study of sensory disturbances in the inferior alveolar nerve after bilateral sagittal split ramus osteotomy

Non-pain-related CRF1 activation in the amygdala facilitates synaptic transmission and pain responses

Activation of mammalian target of rapamycin mediates rat pain-related responses induced by BmK I, a sodium channel-specific modulator